High-dose enzyme replacement therapy in murine Hurler syndrome.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2013.09.008PMID 24100243PMCID PMC4014311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.

  2013cited by this paper
• Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

  2012cited by this paper
• Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.

  2011cited by this paper
• Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.

  2011cited by this paper
• Replacing the Enzyme α-l-Iduronidase at Birth Ameliorates Symptoms in the Brain and Periphery of Dogs with Mucopolysaccharidosis Type I

  2010cited by this paper
• Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment

  2010cited by this paper
• Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy

  2010cited by this paper
• Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.

  2009cited by this paper
• Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

  2008cited by this paper
• Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.

  2008cited by this paper
• Central nervous system therapy for lysosomal storage disorders.

  2008cited by this paper
• Lysosomal storage diseases and the blood-brain barrier.

  2008cited by this paper
• Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.

  2007cited by this paper
• Stress, prefrontal cortex and environmental enrichment: studies on dopamine and acetylcholine release and working memory performance in rats.

  2007cited by this paper
• Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

  2007cited by this paper
• Dose translation from animal to human studies revisited

  2007cited by this paper
• Enzyme replacement therapy in alpha-mannosidosis guinea-pigs.

  2006cited by this paper
• Enzyme replacement therapy in a-mannosidosis guinea-pigs

  2006cited by this paper
• Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy.

  2005cited by this paper
• Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

  2005cited by this paper
• Gene Therapy for a Mucopolysaccharidosis Type I Murine Model with Lentiviral-IDUA Vector

  2005cited by this paper
• Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy

  2005cited by this paper
• Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain?

  2004influential reference
• Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier.

  2004cited by this paper
• Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.

  2004cited by this paper
• Are the Extracellular Pathways a Conduit for the Delivery of Therapeutics to the Brain

  2004cited by this paper
• Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study.

  2004cited by this paper
• Enzyme replacement therapy in a mouse model of aspartylglycosaminuria

  2000cited by this paper
• Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group.

  1998cited by this paper
• Follow-up of nine patients with Hurler syndrome after bone marrow transplantation.

  1998cited by this paper
• Carbohydrate Structures of Recombinant Human α-l-Iduronidase Secreted by Chinese Hamster Ovary Cells*

  1997cited by this paper
• Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome.

  1996cited by this paper
• Enzyme replacement in a canine model of Hurler syndrome.

  1994cited by this paper

• Lipid Nanoparticle-Delivered mRNA Therapy Corrects Neonatal Murine MPS I-H

  2026cites this paper
• Rescue of neurologic disease in mucopolysaccharidosis type II mice via AAV-mediated liver delivery of brain-penetrating iduronate-2-sulfatase

  2025cites this paper
• Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders

  2024cites this paper
• Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model

  2024cites this paper
• Intrathecal or intravenous AAV9-IDUA/RGX-111 at minimal effective dose prevents cardiac, skeletal and neurologic manifestations of murine MPS I

  2024cites this paper
• Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage Disorders

  2024cites this paper
• Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice

  2024cites this paper
• Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome

  2023cites this paper
• Mapping brain networks in MPS I mice and their restoration following gene therapy

  2023cites this paper
• Liver-directed gene therapy corrects neurologic disease in a murine model of mucopolysaccharidosis type I-Hurler

  2022cites this paper
• Targeting the Central Nervous System in Lysosomal Storage Diseases: Strategies to Deliver Therapeutics Across the Blood-Brain Barrier.

  2022cites this paper
• Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I.

  2022cites this paper
• Examination of a blood-brain barrier targeting β-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis

  2021cites this paper
• Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I

  2021cites this paper
• Germline Saturation Mutagenesis Induces Skeletal Phenotypes in Mice

  2021cites this paper
• Targeting Macromolecules to CNS and Other Hard-to-Treat Organs Using Lectin-Mediated Delivery

  2020cites this paper
• Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10

  2020cites this paper
• A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.

  2020cites this paper
• Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B.

  2019cites this paper
• A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases

  2019cites this paper
• Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future

  2019cites this paper
• Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice

  2019cites this paper
• Causal Therapies in Mucopolysaccharidoses: Enzyme Replacement Therapy

  2018cites this paper
• Long-term outcomes of systemic therapies for Hurler syndrome: an international multi-center comparison

  2018cites this paper
• Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing

  2018cites this paper
• P-Tau and Subunit c Mitochondrial ATP Synthase Accumulation in the Central Nervous System of a Woman with Hurler-Scheie Syndrome Treated with Enzyme Replacement Therapy for 12 Years.

  2018cites this paper
• JIMD Reports, Volume 41: Focus Issue: Adults and Metabolism

  2018cites this paper
• Getting the Most: Enhancing Efficacy by Promoting Erythropoiesis and Thrombopoiesis after Gene Therapy in Mice with Hurler Syndrome

  2018cites this paper
• ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome

  2018cites this paper
• Enzymes for Industrial and Pharmaceutical Applications – From Individual to Population Level Impact

  2018cites this paper
• Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016)

  2017cites this paper
• Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice By CNS ‐ Directed , AAV 9 ‐ Mediated Iduronate Sulfatase Gene

  2017cites this paper
• Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System–Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer

  2017cites this paper
• Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease

  2017cites this paper
• Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice.

  2017cites this paper
• Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome

  2017cites this paper
• RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.

  2017influential citation
• Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis.

  2017cites this paper
• Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein.

  2017cites this paper
• Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders.

  2017cites this paper
• Deleterious effects of interruption followed by reintroduction of enzyme replacement therapy on a lysosomal storage disorder.

  2016cites this paper
• CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

  2016cites this paper
• Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I

  2016cites this paper
• Assessment of Dysmyelination with RAFFn MRI: Application to Murine MPS I

  2015cites this paper
• Improving the diagnosis and treatment of MPS I

  2015cites this paper
• Chronic enzyme replacement therapy ameliorates neuropathology in alpha‐mannosidosis mice

  2015cites this paper
• Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: Clinical, biochemical, and pathological improvements

  2015cites this paper
• Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier.

  2015cites this paper
• Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II

  2015cites this paper
• UvA-DARE ( Digital Academic Repository ) Improving the diagnosis and treatment of MPS

  2015influential citation
• RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies

  2015cites this paper
• Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.

  2015cites this paper
• Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I

  2015cites this paper
• Coupling Freshly Isolated CD44+ Infrapatellar Fat Pad‐Derived Stromal Cells with a TGF‐β3 Eluting Cartilage ECM‐Derived Scaffold as a Single‐Stage Strategy for Promoting Chondrogenesis

  2015cites this paper
• Gene delivery strategies for the treatment of mucopolysaccharidoses

  2014influential citation
• Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy.

  2014cites this paper
• Journal Pre-proof Targeting the Central Nervous System in Lysosomal Storage Diseases: Strategies to Deliver Therapeutics Across the Blood-Brain Barrier

  year unknowncites this paper